Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2020The Journal of Headache and PainOpen Access

A prospective real-world analysis of erenumab in refractory chronic migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGiorgio LambruKing's College LondonBHBethany HillGuy's and St Thomas' NHS Foundation TrustMMMadeleine MurphyGuy's and St Thomas' NHS Foundation Trust

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lambru et al. (2020) studied this question.

synapsesocial.com/papers/6a715427febe604dd70a034ahttps://doi.org/10.1186/s10194-020-01127-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy2020 · 173 citations
  2. 2Fremanezumab: First Global Approval2018 · 52 citations
  3. 3Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society2008 · 130 citations
  4. 4Global prevalence of chronic migraine: A systematic review2009 · 714 citations
  5. 5Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition2018 · 10,888 citations